In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
Cretaceous couture: BSF set to unveil T-Rex leather
In London, BSF Enterprise PLC has announced a £15-million (US$19.9-million) fundraise to advance its Lab-Grown Leather technology, with the ultimate goal of showcasing the...
Fore-get plastic: Innoguer wins innovation prize for biopolymer golf ball
In Switzerland, sustainable golf products company Innoguer GmbH has been awarded the prestigious InnoPrix SO! by the Baloise Bank Ltd foundation in recognition of...
Futurama’s biobased films deliver glitter without the litter
In Kansas, specialty materials maker Futamura USA is producing glitter from its parent company’s NatureFlex™ films, which have demonstrated wastewater, marine, and soil biodegradability....